Prognostic impact of T2-weighted CMR imaging for cardiac amyloidosis

European Radiology

Volumn 21, Issue 8, 2011, Pages 1643-1650

  Wassmuth, Ralf ^a   Abdel Aty, Hassan ^a,b   Bohl, Steffen ^a,c   Schulz Menger, Jeanette ^a  

^a HELIOS KLINIKUM BERLIN BUCH   (Germany)

^b Cardio Imaging Center Berlin   (Germany)

^c UNFALLKRANKENHAUS BERLIN   (Germany)

Author keywords

Amyloidosis; Cardiac; Contrast; Magnetic resonance imaging; T2

Indexed keywords

GADOLINIUM PENTETATE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC VALUE; ELECTRON SPIN RESONANCE; FEMALE; FOLLOW UP; HEART AMYLOIDOSIS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HUMAN; MALE; MORTALITY; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; AGED; AMYLOIDOSIS; BIOPSY; CASE-CONTROL STUDIES; CONTRAST MEDIA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; GADOLINIUM DTPA; HEART DISEASES; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; STATISTICS, NONPARAMETRIC;

EID: 80052661460     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-011-2109-3     Document Type: Article

References (44)

1. Falk RH (2005) Diagnosis and management of the cardiac amyloidoses. Circulation 112:2047-2060. (Pubitemid 41377426)
2. Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S (2007) Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 50:2101-2110. (Pubitemid 350117349)
3. Roberts WC, Waller BF (1983) Cardiac amyloidosis causing cardiac dysfunction: analysis of 54 necropsy patients. Am J Cardiol 52:137-146. (Pubitemid 13061341)
4. Rahman JE, Helou EF, Gelzer-Bell R et al (2004) Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol 43:410-415. (Pubitemid 38167701)
5. Eriksson P, Backman C, Eriksson A, Eriksson S, Karp K, Olofsson BO (1987) Differentiation of cardiac amyloidosis and hypertrophic cardiomyopathy. A comparison of familial amyloidosis with polyneuropathy and hypertrophic cardiomyopathy by electrocardiography and echocardiography. Acta Med Scand 221:39-46. (Pubitemid 17041666)
6. Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M (2005) Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 95:535-537. (Pubitemid 40247559)
7. Kristen AV, Meyer FJ, Perz JB et al (2005) Risk stratification in cardiac amyloidosis: Novel approaches. Transplantation 80:S151- S155. (Pubitemid 41552928)
8. Nordlinger M, Magnani B, Skinner M, Falk RH (2005) Is elevated plasma b-natriuretic peptide in amyloidosis simply a function of the presence of heart failure? Am J Cardiol 96:982-984. (Pubitemid 41362524)
9. Dispenzieri A, Gertz MA, Kyle RA et al (2004) Serum cardiac troponins and n-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 22:3751- 3757. (Pubitemid 41095215)
10. Kim RJ, Shah DJ, Judd RM (2003) How we perform delayed enhancement imaging. J Cardiovasc Magn Reson 5:505-514. (Pubitemid 36859434)
11. Choudhury L, Mahrholdt H, Wagner A et al (2002) Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 40:2156-2164. (Pubitemid 36005903)
12. Moon JC, Reed E, Sheppard MN et al (2004) The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 43:2260-2264. (Pubitemid 38757595)
13. Hunold P, Schlosser T, Vogt FM et al (2005) Myocardial late enhancement in contrast-enhanced cardiac MRI: Distinction between infarction scar and non-infarction-related disease. Am J Roentgenol 184:1420-1426. (Pubitemid 43821809)
14. Lim RP, Srichai MB, Lee VS (2007) Non-ischemic causes of delayed myocardial hyperenhancement on MRI. Am J Roentgenol 188:1675-1681. (Pubitemid 46866875)
15. Bohl S, Wassmuth R, Abdel-Aty H et al (2008) Delayed enhancement cardiac magnetic resonance imaging reveals typical patterns of myocardial injury in patients with various forms of non-ischemic heart disease. Int J Cardiovasc Imaging 24:597-607.
16. Maceira AM, Joshi J, Prasad SK et al (2005) Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111:186-193. (Pubitemid 40139730)
17. Perugini E, Rapezzi C, Piva T et al (2006) Noninvasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart 92(3):343-349.
18. Vogelsberg H, Mahrholdt H, Deluigi CC et al (2008) Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: Noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 51:1022-1030. (Pubitemid 351318125)
19. Seeger A, Klumpp B, Kramer U et al (2009) MRI assessment of cardiac amyloidosis: experience of six cases with review of the current literature. Br J Radiol 82:337-342.
20. Abdel-Aty H, Boye P, Zagrosek A et al (2005) Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol 45:1815-1822. (Pubitemid 40779862)
21. Friedrich MG, Strohm O, Schulz-Menger J, Marciniak H, Luft FC, Dietz R (1998) Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation 97:1802-1809. (Pubitemid 28213624)
22. Anderson JL, Horne BD, Pennell DJ (2005) Atrial dimensions in health and left ventricular disease using cardiovascular magnetic resonance. J Cardiovasc Magn Reson 7:671-675. (Pubitemid 41176833)
23. Maceira AM, Prasad SK, Khan M, Pennell DJ (2006) Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson 8:417-426.
24. Gean-Marton AD, Kirsch CF, Vezina LG, Weber AL (1991) Focal amyloidosis of the head and neck: evaluation with CT and MR imaging. Radiology 181:521-525.
25. Celletti F, Fattori R, Napoli G et al (1999) Assessment of restrictive cardiomyopathy of amyloid or idiopathic etiology by magnetic resonance imaging. Am J Cardiol 83(798-801):a10.
26. Barnes ME, Miyasaka Y, Seward JB et al (2004) Left atrial volume in the prediction of first ischemic stroke in an elderly cohort without atrial fibrillation. Mayo Clin Proc 79:1008-1014. (Pubitemid 39007021)
27. Fattori R, Rocchi G, Celletti F, Bertaccini P, Rapezzi C, Gavelli G (1998) Contribution of magnetic resonance imaging in the differential diagnosis of cardiac amyloidosis and symmetric hypertrophic cardiomyopathy. Am Heart J 136:824-830. (Pubitemid 28506882)
28. Berk JL (2005) Pleural effusions in systemic amyloidosis. Curr Opin Pulm Med 11:324-328. (Pubitemid 41073157)
29. Asaumi J, Yanagi Y, Hisatomi M, Konouchi H, Kishi K (2001) CT and MR imaging of localized amyloidosis. Eur J Radiol 39:83-87. (Pubitemid 32755924)
30. Sueyoshi E, Sakamoto I, Okimoto T, Hayashi K, Tanaka K, Toda G (2006) Cardiac amyloidosis: typical imaging findings and diffuse myocardial damage demonstrated by delayed contrastenhanced MRI. Cardiovasc Intervent Radiol 29:710-712. (Pubitemid 43823029)
31. vanden Driesen RI, Slaughter RE, Strugnell WE (2006) MR findings in cardiac amyloidosis. AJR Am J Roentgenol 186:1682- 1685. (Pubitemid 46112533)
32. Bucciarelli-Ducci C, Locca D, Barbeau G, Prasad SK (2007) Value of cardiovascular magnetic resonance for determining cardiac involvement in systemic amyloidosis. Eur Heart J 28:1186. (Pubitemid 47343827)
33. Syed IS, Glockner JF, Feng D et al (2010) Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 3:155-164.
34. Leeson CP, Myerson SG, Walls GB, Neubauer S, Ormerod OJ (2006) Atrial pathology in cardiac amyloidosis: evidence from ECG and cardiovascular magnetic resonance. Eur Heart J 27:1670. (Pubitemid 44025352)
35. Van Geluwe F, Dymarkowski S, Crevits I, De Wever W, Bogaert J (2006) Amyloidosis of the heart and respiratory system. Eur Radiol 16:2358-2365. (Pubitemid 44349885)
36. Cheng AS, Banning AP, Mitchell AR, Neubauer S, Selvanayagam JB (2006) Cardiac changes in systemic amyloidosis: visualisation by magnetic resonance imaging. Int J Cardiol 113:E21-E23. (Pubitemid 44648376)
37. Ruberg FL, Appelbaum E, Davidoff R et al (2009) Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol 103:544-549.
38. Austin BA, Tang WH, Rodriguez ER et al (2009) Delayed hyperenhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging 2:1369-1377.
39. Lyne JC, Petryka J, Pennell DJ (2008) Atrial enhancement by cardiovascular magnetic resonance in cardiac amyloidosis. Eur Heart J 29:212.
40. Gertz MA, Comenzo R, Falk RH et al (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (al): a consensus opinion from the 10th international symposium on amyloid and amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 79:319-328. (Pubitemid 41098849)
41. Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ (2008) Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 10:54.
42. Sparrow P, Amirabadi A, Sussman MS, Paul N, Merchant N (2009) Quantitative assessment of myocardial T2 relaxation times in cardiac amyloidosis. J Magn Reson Imaging 30:942-946.
43. Krombach GA, Hahn C, Tomars M et al (2007) Cardiac amyloidosis: MR imaging findings and T1 quantification, comparison with control subjects. J Magn Reson Imaging 25:1283- 1287. (Pubitemid 46870288)
44. Hosch W, Bock M, Libicher M et al (2007) MR-relaxometry of myocardial tissue: significant elevation of T1 and T2 relaxation times in cardiac amyloidosis. Invest Radiol 42:636-642. (Pubitemid 47262932)